NCT Number: NCT00069537
Continuous Glucose Monitors for Children With Diabetes Mellitus
Good control of blood glucose levels is important in preventing complications from diabetes. This study assessed the accuracy and reliability of two FDA-approved continuous glucose monitors, the Continuous Glucose Monitoring System (CGMS) and the GlucoWatch G2 Biographer (GW2B), in children with type 1 diabetes mellitus (T1DM).
Looking for future studies?
Notify MeKey information
Conditions
Age range
1 year–17 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 4
Primary location
Division of Pediatric Endocrinology and Diabetes, Stanford University, Stanford, California, United States
About this study
Intensive control of blood glucose levels has been shown to substantially prevent or delay complications of T1DM in adolescents and adults. The major limitation to implementation of intensive glycemic control is hypoglycemia. Younger children may be at increased risk for hypoglycemia and the risk/benefit ratio of intensive glycemic control may be less favorable in this population. Intensive therapy has not been systematically evaluated in children less than 13 years of age. This study was conducted by the Diabetes Research in Children Network (DirecNet) to assess the accuracy of the CGMS and the GW2B glucose monitors in comparison with standard blood glucose measurements in an inpatient setting.
During 24-hour clinical research center stays at five clinical centers, approximately 90 children and adolescents with T1DM (1 to 17 years of age) wore two FDA-approved continuous glucose monitors, CGMS and GW2B, and had frequent serum glucose determinations during the day and night. To assess glucose monitor function during periods of rising and falling blood glucose, insulin-induced hypoglycemia and meal-induced hyperglycemia tests were also performed.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Clinical diagnosis of type 1 diabetes mellitus for at least 1 year prior to study entry
- For children over 2 years of age, body mass index between the 5th and 95th percentile for age and gender
- Weight >= 12 kg (26.5 lbs) if < 7 years of age and >= 16 kg (35 lbs) if >7 years of age
- Normal hematocrit
Exclusion criteria
- Current use of glucocorticoids
- Skin or other medical disorders that would affect completion of the study
- History of seizures other than those attributable to either hypoglycemia or high fever
Treatment and study plan
The Continuous Glucose Monitoring System (CGMS™)
DevicePrimary outcomes
-
Accuracy of the GlucoWatch G2 Biographer and CGMS
Sponsors and collaborators
Lead sponsor
Jaeb Center for Health Research
Other
Collaborators
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Registry information
Official study title
DirecNet Inpatient Study to Test the Accuracy of Continuous Blood Glucose Monitoring Devices in Children With Type 1 Diabetes
Important dates
- Study start
- 2002
- Study completion
- 2002
- First posted
- Sep 30, 2003
- Registry last updated
- Sep 5, 2016
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)
NCT00690066
Autoimmune Diseases, Diabetes Mellitus
Birmingham, Alabama, United States
View Trial DetailsFeasibility of Closed-loop Automated Insulin Delivery System by Primary Care & Endocrinology, in Person & Via Telehealth
NCT05168657
Autoimmune Diabetes, Autoimmune Diseases
Aurora, Colorado, United States
View Trial DetailsA Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study in Patients With New-onset Type 1 Diabetes
NCT02814838
Autoimmune Diseases, Diabetes Mellitus
Brussels, Belgium
View Trial DetailsInsulin Pump Therapy in Adolescents With Newly Diagnosed Type 1 Diabetes (T1D)
NCT00357890
Autoimmune Diseases, Diabetes Mellitus
Jacksonville, Florida, United States
View Trial Details